X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-11-12 | ITCI | Halstead Michael | Pres | S - Sale+OE | $88.79 | -41,583 | 0 | -100% | -$3,692,100 | |||||
| DM | 2024-08-29 | ITCI | Mates Sharon | COB, CEO | S - Sale+OE | $72.70 | -70,000 | 1,070,329 | -6% | -$5,089,236 | |||||
| DM | 2024-08-26 | ITCI | Mates Sharon | COB, CEO | S - Sale+OE | $73.54 | -95,925 | 1,070,329 | -8% | -$7,054,085 | |||||
| DM | 2024-08-21 | ITCI | Mates Sharon | COB, CEO | S - Sale+OE | $75.05 | -121,073 | 1,070,329 | -10% | -$9,086,738 | |||||
| D | 2024-08-16 | ITCI | Neumann Mark | EVP, Chief Commercial Officer | S - Sale+OE | $75.08 | -18,714 | 29,700 | -39% | -$1,405,047 | |||||
| D | 2024-06-24 | ITCI | Riggs Rory B | Dir | S - Sale+OE | $75.57 | -4,462 | 116,600 | -4% | -$337,193 | |||||
| D | 2024-06-18 | ITCI | Van Nostrand Robert L | Dir | S - Sale+OE | $75.91 | -20,000 | 9,690 | -67% | -$1,518,199 | |||||
| DM | 2024-03-07 | ITCI | Mates Sharon | COB, Pres, CEO | S - Sale+OE | $66.07 | -61,277 | 1,050,309 | -6% | -$4,048,400 | |||||
| DM | 2024-03-07 | ITCI | Hineline Lawrence J. | SVP of Finance, CFO | S - Sale+OE | $66.32 | -23,253 | 0 | -100% | -$1,542,147 | |||||
| DM | 2024-03-07 | ITCI | Halstead Michael | EVP, GC | S - Sale+OE | $66.09 | -20,477 | 0 | -100% | -$1,353,235 | |||||
| DM | 2024-03-07 | ITCI | Neumann Mark | EVP, Chief Commercial Officer | S - Sale+OE | $66.23 | -20,477 | 29,700 | -41% | -$1,356,110 | |||||
| DM | 2024-03-07 | ITCI | Durgam Suresh K. | EVP, Chief Medical Officer | S - Sale+OE | $66.21 | -10,162 | 19,803 | -34% | -$672,791 | |||||
| D | 2024-02-27 | ITCI | Van Nostrand Robert L | Dir | S - Sale+OE | $72.93 | -20,000 | 9,611 | -68% | -$1,458,650 | |||||
| D | 2024-02-26 | ITCI | Halstead Michael | EVP, GC | S - Sale+OE | $69.53 | -7,907 | 0 | -100% | -$549,784 | |||||
| D | 2024-02-26 | ITCI | Hineline Lawrence J. | SVP of Finance, CFO | S - Sale+OE | $69.43 | -13,337 | 0 | -100% | -$925,961 | |||||
| D | 2024-02-26 | ITCI | Mates Sharon | COB, Pres, CEO | S - Sale+OE | $69.79 | -22,590 | 1,050,309 | -2% | -$1,576,464 | |||||
| D | 2024-02-26 | ITCI | Durgam Suresh K. | EVP, Chief Medical Officer | S - Sale+OE | $70.17 | -4,112 | 9,488 | -30% | -$288,534 | |||||
| D | 2024-02-26 | ITCI | Neumann Mark | EVP, Chief Commercial Officer | S - Sale+OE | $70.13 | -7,907 | 29,700 | -21% | -$554,491 | |||||
| D | 2024-02-26 | ITCI | Marcus Joel S | Dir | S - Sale+OE | $68.68 | -26,328 | 49,662 | -35% | -$1,808,253 | |||||
2024-02-02 | ITCI | Halstead Michael | EVP, GC | S - Sale | $66.42 | -11,860 | 0 | -100% | -$787,719 | ||||||
2024-02-02 | ITCI | Mates Sharon | COB, Pres, CEO | S - Sale | $67.07 | -33,885 | 1,050,309 | -3% | -$2,272,694 | ||||||
2024-02-02 | ITCI | Neumann Mark | EVP, Chief Commercial Officer | S - Sale | $67.15 | -11,860 | 29,700 | -29% | -$796,367 | ||||||
2024-02-02 | ITCI | Hineline Lawrence J. | SVP of Finance, CFO | S - Sale | $66.62 | -11,183 | 0 | -100% | -$745,037 | ||||||
2024-02-02 | ITCI | Durgam Suresh K. | EVP, Chief Medical Officer | S - Sale | $67.19 | -6,167 | 5,693 | -52% | -$414,355 | ||||||
| DM | 2024-01-16 | ITCI | Mates Sharon | COB, Pres, CEO | S - Sale+OE | $66.27 | -191,362 | 1,050,309 | -15% | -$12,680,892 | |||||
| D | 2024-01-11 | ITCI | Halstead Michael | EVP, GC | S - Sale+OE | $66.83 | -50,000 | 0 | -100% | -$3,341,699 | |||||
| D | 2024-01-02 | ITCI | Durgam Suresh K. | EVP, Chief Medical Officer | S - Sale+OE | $70.60 | -62,282 | 0 | -100% | -$4,397,113 | |||||
2023-12-13 | ITCI | Durgam Suresh K. | EVP, Chief Medical Officer | S - Sale | $65.00 | -21,262 | 0 | -100% | -$1,382,030 | ||||||
| D | 2023-11-06 | ITCI | Neumann Mark | EVP, Chief Commercial Officer | S - Sale+OE | $55.63 | -42,393 | 29,700 | -59% | -$2,358,152 | |||||
| M | 2023-09-18 | ITCI | Mates Sharon | COB, Pres, CEO | S - Sale | $53.94 | -100,000 | 1,050,309 | -9% | -$5,394,065 | |||||
| D | 2023-08-07 | ITCI | Neumann Mark | EVP, Chief Commercial Officer | S - Sale+OE | $58.79 | -55,300 | 45,339 | -55% | -$3,251,087 | |||||
2023-07-17 | ITCI | Durgam Suresh K. | EVP, Chief Medical Officer | S - Sale | $65.00 | -1,842 | 21,262 | -8% | -$119,730 | ||||||
| D | 2023-06-14 | ITCI | Hineline Lawrence J. | SVP of Finance CFO | S - Sale+OE | $63.97 | -81,854 | 0 | -100% | -$5,236,329 | |||||
| D | 2023-04-17 | ITCI | Van Nostrand Robert L | Dir | S - Sale+OE | $63.00 | -10,000 | 9,345 | -52% | -$630,000 | |||||
2023-03-28 | ITCI | Neumann Mark | EVP, Chief Commercial Officer | S - Sale | $54.31 | -15,604 | 45,339 | -26% | -$847,380 | ||||||
| D | 2023-03-13 | ITCI | Durgam Suresh K. | EVP, Chief Medical Officer | S - Sale+OE | $45.04 | -7,344 | 23,104 | -24% | -$330,794 | |||||
| DM | 2023-03-10 | ITCI | Neumann Mark | EVP, Chief Commercial Officer | S - Sale+OE | $43.84 | -12,308 | 60,943 | -17% | -$539,599 | |||||
| DM | 2023-03-10 | ITCI | Halstead Michael | EVP, GC | S - Sale+OE | $43.66 | -24,052 | 0 | -100% | -$1,050,092 | |||||
| DM | 2023-03-10 | ITCI | Hineline Lawrence J. | SVP of Finance CFO | S - Sale+OE | $43.55 | -21,245 | 0 | -100% | -$925,225 | |||||
| DM | 2023-03-10 | ITCI | Mates Sharon | COB, Pres, CEO | S - Sale+OE | $43.76 | -62,335 | 1,150,309 | -5% | -$2,727,841 | |||||
2023-03-01 | ITCI | Neumann Mark | EVP, Chief Commercial Officer | S - Sale | $50.01 | -7,241 | 49,199 | -13% | -$362,122 | ||||||
| D | 2023-02-24 | ITCI | Neumann Mark | EVP, Chief Commercial Officer | S - Sale+OE | $47.12 | -4,046 | 56,440 | -7% | -$190,648 | |||||
| D | 2023-02-24 | ITCI | Durgam Suresh K. | SVP, Chief Medical Officer | S - Sale+OE | $47.14 | -7,906 | 23,104 | -25% | -$372,689 | |||||
| D | 2023-02-24 | ITCI | Halstead Michael | EVP, GC | S - Sale+OE | $47.03 | -7,906 | 0 | -100% | -$371,819 | |||||
| D | 2023-02-24 | ITCI | Hineline Lawrence J. | SVP of Finance CFO | S - Sale+OE | $47.03 | -7,455 | 0 | -100% | -$350,609 | |||||
| D | 2023-02-24 | ITCI | Mates Sharon | COB, Pres, CEO | S - Sale+OE | $47.03 | -22,590 | 1,130,309 | -2% | -$1,062,408 | |||||
| D | 2023-02-21 | ITCI | Neumann Mark | EVP, Chief Commercial Officer | S - Sale+OE | $47.01 | -3,898 | 52,580 | -7% | -$183,246 | |||||
| D | 2023-02-21 | ITCI | Durgam Suresh K. | SVP, Chief Medical Officer | S - Sale+OE | $46.84 | -8,354 | 23,104 | -27% | -$391,304 | |||||
| D | 2023-02-21 | ITCI | Halstead Michael | EVP, GC | S - Sale+OE | $46.84 | -11,139 | 0 | -100% | -$521,699 | |||||
| DM | 2023-02-17 | ITCI | Hineline Lawrence J. | SVP of Finance CFO | S - Sale+OE | $49.34 | -64,411 | 0 | -100% | -$3,178,354 | |||||
| D | 2023-02-21 | ITCI | Mates Sharon | COB, Pres, CEO | S - Sale+OE | $46.83 | -27,848 | 1,100,309 | -2% | -$1,304,000 | |||||
2022-12-19 | ITCI | Marcus Joel S | Dir | S - Sale | $50.82 | -5,000 | 39,233 | -11% | -$254,100 | ||||||
2022-12-13 | ITCI | Mates Sharon | COB, Pres, CEO | S - Sale | $55.00 | -33,083 | 1,100,309 | -3% | -$1,819,565 | ||||||
| D | 2022-12-01 | ITCI | Halstead Michael | EVP, GC | S - Sale+OE | $53.73 | -50,000 | 0 | -100% | -$2,686,514 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |